As a leader in medicinal chemistry research and custom synthesis, we provide partners with compound synthesis options and support across the full spectrum of preclinical drug discovery. Our partners greatly appreciate our pragmatic and results-oriented approach to both synthetic and drug discovery projects, as well as our ability to rapidly solicit multi-disciplinary support within IRBM toward overcoming scientific and practical challenges.
Our team has a strong synthetic pedigree and experience across a range of structural classes including peptidomimetics, steroids, nucleosides and a vast number of heterocyclic drug scaffolds. Our facilities are state of the art, allowing both single compound and parallel synthesis, employing the most modern transition metal catalysed couplings, organocatalysis and photoredox chemistries.
Our legacy in drug research includes the discovery of three marketed drugs (Isentress®, Grazoprevir® and Zejula®) and over 30 preclinical and clinical development compounds. Our experience across a range of different disease areas continues to expand, and includes oncology, antivirals, diabetes, obesity, cardiovascular and CNS indications.
Our know-how in advancing integrated drug discovery projects adds value to our partner’s research both in the early phases and late stage of preclinical drug discovery.